News

The single-dose study is the first stage of the Phase I trial, which the company is currently carrying out for the oral agent of a new molecular entity

"Asia-Pacific is poised to become the world’s next biopharma powerhouse, not least because of its growing number of emerging companies with promising pipelines," said Senior Vice President Ross

Aubagio is indicated as monotherapy for the treatment of RRMS to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability. "Aubagio is proving

The operating property has been occupied by the Company since 2004 pursuant to a lease, and is approximately 25,000 sq. ft. The adjoining property includes a building of

"The grant of this IND marks the achievement of the second important milestone for COTI-2 in 2015 and builds on the Orphan Drug designation received for ovarian cancer

"While we are disappointed by the Court’s decision to uphold this ruling, we intend to continue our strong efforts to convey the significant benefits of NAMENDA XR to

The study, called SARIL-RA-TARGET, evaluated the efficacy and safety of two subcutaneous sarilumab doses versus placebo, added to non-biologic disease modifying anti-rheumatic drugs (DMARD) therapy in RA patients

The results of this trial to date demonstrated that five out of seven patients responded to the treatment. CD30-directed CAR-T cell therapy was demonstrated in this trial to

Brodalumab, an investigational IL-17 inhibitor, is in development for patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis. The decision was based on events of suicidal ideation